Hola,
¿eres nuevo aquí?

Regístrate gratis y conecta tu empresa con financiación pública, partners y proyectos.

Tengo cuenta

Regístrate

Ver video

KineTic

Financiado

Cerrado

New Reagents for Quantifying the Routing and Kinetics of T cell Activation

The activation of The activation of cytotoxic T-cells (CTLs) marks the key step in the adaptive immune response against cancer and viral infections. Vaccines that activate the CTL-response against tumours are currently hotly pursu... ver más

31/01/2026

ULEI

2M€

Presupuesto del proyecto: 2M€

Líder del proyecto

UNIVERSITEIT LEIDEN No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Fecha límite participación Sin fecha límite de participación.

Ver 2 Participantes

Financiación concedida El organismo H2020 notifico la concesión del proyecto el día 2020-02-12

ERC-2019-COG: ERC Consolidator Grant

I+D

Cerrada hace 5 años

0% 100% 100%

Información adicional privada

No hay información privada compartida para este proyecto. Habla con el coordinador.

2 Participantes

ULEI

2.00M€ | Lider

PROBELTE

434.24K€ | Participante

Conecta tu I+D

¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video

Proyectos interesantes

DevoSignGammaDelta Tracking T cell development and TCR proximal signalling 161K€ Cerrado

PID2020-118529RB-I00 EXPLOTANDO LOS DETERMINANTES MOLECULARES DE LA RESPUESTA T A... 218K€ Cerrado

PID2020-116393RB-I00 NUEVA GENERACION DE INMUNOTERAPIAS CONTRA CANCER BASADAS EN... 257K€ Cerrado

PHAGODC Integrative phagosomal biology antigen presentation and dev... 2M€ Cerrado

POST-IT Pathogen Oriented SNARE Trafficking for Immune Tailoring 2M€ Cerrado

MUTAEDITING Mutation driven immunoediting of human cancer? 2M€ Cerrado

Duración del proyecto: 71 meses Fecha Inicio: 2020-02-12
Fecha Fin: 2026-01-31

Líder del proyecto

UNIVERSITEIT LEIDEN No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Presupuesto del proyecto 2M€

Fecha límite de participación Sin fecha límite de participación.

Descripción del proyecto The activation of The activation of cytotoxic T-cells (CTLs) marks the key step in the adaptive immune response against cancer and viral infections. Vaccines that activate the CTL-response against tumours are currently hotly pursued, with those targeting tumour-specific mutations now reaching the clinic. However, the capacity of these vaccines to actually activate CTLs is low and rational design improvements are needed to broaden their application. For this, better in vivo knowledge on the processes leading to CTL-activation is needed. CTLs are activated by dendritic cells. These cells take up the vaccine, and process it to 8-10-mer peptides for presentation to CTLs on MHC-I complexes. A process called cross-presentation. In this proposal, I aim to quantify key unknowns of this pathway, relating to its kinetics and the subcellular route a vaccine takes to reach the MHC-loading site. I will: a) Quantify the kinetics of peptide-MHC appearance, persistence and disappearance, in vivo using vaccines carrying bioorthogonal protecting/blocking groups that allow me to chemically activate, and stop, the recognition by CTLs in time. b) I will also study the sub-cellular route(s) the vaccine antigens take in vivo, by developing a second family deprotection and blocking reagents that are targeted to specific organelles. This localised vaccine activation (or de-activation) will allow me to study the different proposed subcellular routes of the antigen in isolation and assess the importance of the many proposed subcellular routes in vivo to overall cross-presentation success. The kinetic and routing information obtained from this new set of reagents, will allow me to shed light on some of the key unknowns relating to cross-presentation in vivo, and assess their importance to the success of CTL-activation. By using vaccine-models closely related to existing cancer vaccines, these data will in turn serve to support the rational design of better anti-tumour vaccines.

Conecta tu I+D

Entra hoy

¿Olvidé mi contraseña?

Financiación

Empresas

CTIs/Universidades

Proyectos

Investigadores